Annals of R.S.C.B., ISSN: 1583-6258, Vol. 24, Issue 2, 2020, Pages. 1448 -1462 Received 24 October 2020; Accepted 15 December 2020. 1448 http://annalsofrscb.ro Clinical Study of Acute Myelogenous Leukaemia Patients Data Vivek Tyagi 1 , Rajiv Saksena 2 , Ashok Kumar 2 and Jitendra Kumar 3 * 1 Department of Statistics, NAS College, Meerut, INDIA 2 Department of Statistics, University of Lucknow, INDIA 3 Directorate of Economics and Statistics, Planning Department, Delhi, INDIA (*Corresponding Author: statsjkumar@gmail.com) ABSTRACT Acute leukaemia is a malignancy of the white blood cells that is aggressive and progressing. The illness can be further divided into two subtypes, each of which affects different types of white blood cells. Since, Myeloid cells are a type of white blood cell that protects the body against parasites, reduces the frequency of tissue damage, and fights bacterial infections. Lymphocytes are primarily involved in the defence against viral infections. The aim of this study is to analyze the lifetime of the survival patients with acute myeloid leukemia. Since, clinical data provides important tools for a possible development of surveillance system for the acute myeloid leukemia. In survival analysis, to performing an experiment up to a certain period of time or getting the desired number of failures is time-consuming and costly. Many of the available observations remains censored and only give the survival information of testing units up to a noted time and not about the exact failure times. In this article, the Akshaya distribution is considered as a survival lifetime model. Censoring time is also assumed to follow Akshaya distribution with a different parameter. A survival study will be perform for the Acute Myelogenous Leukaemia patients data. Keywords: Acute Myelogenous Leukaemia, Akshaya Distribution, Random Censoring, Maximum Likelihood Estimation, Bayesian Analysis. 1. Introduction The Acute myelogenous leukaemia is a blood and bone marrow cancer in human beings, which affects the spongy region inside bones where blood cells are produced. Sincethe word ”acute” denotes the disease’s rapid progression in acute myelogenous leukemia. Myelogenous leukaemia is defined as a kind of leukaemia that affects a group of white blood cells known as myeloid cells, which develop into various types of mature blood cells such as red blood cells, white blood cells, and platelets. Acute myelogenous leukemia is also known as acute myeloid leukemia, acute myeloblastic leukemia, acute granulocytic leukemia and acute nonlymphocytic leukemia. Acute myelogenous leukaemia develops when the genetic material or Deoxyribonucleic acid (DNA) of a bone marrow cell changes. The DNA of a cell includes the instructions that tell it what to do. Normally, the cell’s DNA directs it to grow at a predetermined rate and die at a specific time. The mutations in acute myelogenous leukaemia tell the bone marrow cell to keep growing and dividing. Acute myelogenous leukemia occurs when a bone marrow cell develops changes in its genetic material or DNA. A cell’s DNA contains the instructions that tell a cell what to do. The Blood cell production becomes uncontrollable as a result of this. The bone marrow generates immature cells that progress into myeloblasts, which are leukemic white blood cells. These dysfunctional cells can accumulate and crowd out healthy cells